The DHRS1 (short-chain dehydrogenase/reductase family member 1) antibody is a tool used to detect and study the DHRS1 protein, a member of the short-chain dehydrogenase/reductase (SDR) superfamily. DHRS1 is an NAD+/NADP+-dependent enzyme implicated in redox reactions, though its precise physiological substrates and functions remain under investigation. It shares structural features with other SDR enzymes, including a conserved cofactor-binding domain and a catalytic triad, but exhibits unique tissue-specific expression patterns, with higher levels observed in the liver, kidney, and gastrointestinal tract.
Research suggests DHRS1 may play roles in cellular differentiation, apoptosis, and metabolic regulation. Its dysregulation has been linked to diseases such as cancer, where it may act as a tumor suppressor or promoter depending on context. For example, reduced DHRS1 expression correlates with poor prognosis in hepatocellular carcinoma, while overexpression is associated with gastric cancer progression.
DHRS1 antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein expression, localization, and interactions in both normal and pathological tissues. These antibodies aid in elucidating DHRS1's role in disease mechanisms and potential therapeutic targeting. Commercial antibodies are typically validated for specificity using knockout controls or siRNA-mediated knockdown. Ongoing studies aim to clarify DHRS1's enzymatic activity, regulatory pathways, and clinical relevance across different biological contexts.